RNA

Avidity Biosciences, Inc. Common Stock#13 · 2024EPB

Yearly return

+218%

Peak return

+511%

Max drawdown

-49%

ADR (20 days)

+5.8%

Base

15 days / -18.9%

Prior run

+175%

Breakout volume

10.1x

Pivot

$30.84

Catalyst Earnings/Guidance2024-06-13Avidity (RNA) Up 33% on Rare Muscle Disease Study ResultsZacks Investment Research

Earnings, Guidance oder Umsatz-/EPS-Revision als Neubewertungsanker.

Healthcare · Healthcare & Biotech

Continue in the full Atlas

Drawing, alerts, replay and the live scanner built on the same criteria are part of WickedDesk. Compare RNA with the current market directly.